PURPOSE: The kinesin spindle protein (KSP) is essential for separation of spindle poles during mitosis. Its inhibition results in mitotic arrest. This phase I trial examined safety, tolerability, dose-limiting toxicity (DLT), maximum tolerated dose (MTD), pharmacokinetic parameters, and anti-tumor activity of MK-0731, a potent inhibitor of KSP. EXPERIMENTAL DESIGN: In part 1, patients with advanced solid tumors received MK-0731 intravenously over 24 h every 21 days starting at 6 mg/m(2), escalating until MTD was reached. In part 2, patients with taxane-resistant tumors received the MTD. Plasma samples were collected to analyze the pharmacokinetics of MK-0731. Tumor response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. RESULTS: In part 1, 21 patients (median age 63 years) were treated with MK-0731 at doses ranging from 6 to 48 mg/m(2)/24 h for median four cycles. The dose-limiting toxicity was neutropenia and the MTD was 17 mg/m(2)/24 h. At the MTD, AUC (±SD) was 10.5 (±7.3) μM × hour, clearance (±SD) was 153 mL/min (±84), and t(1/2) was 5.9 h. In part 2, 22 patients received the MTD and there were no DLTs. Although there were no objective tumor responses, four patients (with cervical, non-small cell lung, and ovarian cancers) had prolonged stable disease. CONCLUSIONS: MK-0731 at the MTD of 17 mg/m(2)/day every 21 days in patients with solid tumors had few grade 3 and 4 toxicities with the major DLTs at higher doses being myelosuppression. Anti-tumor efficacy was suggested by the length of stable disease in selected patients with taxane-resistant tumors.
PURPOSE: The kinesin spindle protein (KSP) is essential for separation of spindle poles during mitosis. Its inhibition results in mitotic arrest. This phase I trial examined safety, tolerability, dose-limiting toxicity (DLT), maximum tolerated dose (MTD), pharmacokinetic parameters, and anti-tumor activity of MK-0731, a potent inhibitor of KSP. EXPERIMENTAL DESIGN: In part 1, patients with advanced solid tumors received MK-0731 intravenously over 24 h every 21 days starting at 6 mg/m(2), escalating until MTD was reached. In part 2, patients with taxane-resistant tumors received the MTD. Plasma samples were collected to analyze the pharmacokinetics of MK-0731. Tumor response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. RESULTS: In part 1, 21 patients (median age 63 years) were treated with MK-0731 at doses ranging from 6 to 48 mg/m(2)/24 h for median four cycles. The dose-limiting toxicity was neutropenia and the MTD was 17 mg/m(2)/24 h. At the MTD, AUC (±SD) was 10.5 (±7.3) μM × hour, clearance (±SD) was 153 mL/min (±84), and t(1/2) was 5.9 h. In part 2, 22 patients received the MTD and there were no DLTs. Although there were no objective tumor responses, four patients (with cervical, non-small cell lung, and ovarian cancers) had prolonged stable disease. CONCLUSIONS:MK-0731 at the MTD of 17 mg/m(2)/day every 21 days in patients with solid tumors had few grade 3 and 4 toxicities with the major DLTs at higher doses being myelosuppression. Anti-tumor efficacy was suggested by the length of stable disease in selected patients with taxane-resistant tumors.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Weikang Tao; Victoria J South; Yun Zhang; Joseph P Davide; Linda Farrell; Nancy E Kohl; Laura Sepp-Lorenzino; Robert B Lobell Journal: Cancer Cell Date: 2005-07 Impact factor: 31.743
Authors: Weikang Tao; Victoria J South; Ronald E Diehl; Joseph P Davide; Laura Sepp-Lorenzino; Mark E Fraley; Kenneth L Arrington; Robert B Lobell Journal: Mol Cell Biol Date: 2006-11-13 Impact factor: 4.272
Authors: Kyle D Holen; Chandra P Belani; George Wilding; Suresh Ramalingam; Jennifer L Volkman; Ramesh K Ramanathan; Lakshmi S Vasist; Carolyn J Bowen; Jeffrey P Hodge; Mohammed M Dar; Peter T C Ho Journal: Cancer Chemother Pharmacol Date: 2010-05-12 Impact factor: 3.333
Authors: Christopher W Lee; Karl Bélanger; Sanjay C Rao; Teresa M Petrella; Richard G Tozer; Lori Wood; Kerry J Savage; Elizabeth A Eisenhauer; Timothy W Synold; Nancy Wainman; Lesley Seymour Journal: Invest New Drugs Date: 2007-10-26 Impact factor: 3.850
Authors: Roman Sakowicz; Jeffrey T Finer; Christophe Beraud; Anne Crompton; Evan Lewis; Alex Fritsch; Yan Lee; John Mak; Robert Moody; Rebecca Turincio; John C Chabala; Paul Gonzales; Stephanie Roth; Steve Weitman; Kenneth W Wood Journal: Cancer Res Date: 2004-05-01 Impact factor: 12.701
Authors: S P Blagden; L R Molife; A Seebaran; M Payne; A H M Reid; A S Protheroe; L S Vasist; D D Williams; C Bowen; S J Kathman; J P Hodge; M M Dar; J S de Bono; M R Middleton Journal: Br J Cancer Date: 2008-03-04 Impact factor: 7.640
Authors: Eric Polley; Mark Kunkel; David Evans; Thomas Silvers; Rene Delosh; Julie Laudeman; Chad Ogle; Russell Reinhart; Michael Selby; John Connelly; Erik Harris; Nicole Fer; Dmitriy Sonkin; Gurmeet Kaur; Anne Monks; Shakun Malik; Joel Morris; Beverly A Teicher Journal: J Natl Cancer Inst Date: 2016-05-31 Impact factor: 13.506
Authors: John F Gerecitano; Joe J Stephenson; Nancy L Lewis; Anna Osmukhina; Jianguo Li; Kaida Wu; Zhiping You; Dennis Huszar; Jeffrey M Skolnik; Gary K Schwartz Journal: Invest New Drugs Date: 2012-05-22 Impact factor: 3.850
Authors: Edward J Wojcik; Rebecca S Buckley; Jessica Richard; Liqiong Liu; Thomas M Huckaba; Sunyoung Kim Journal: Gene Date: 2013-08-14 Impact factor: 3.688
Authors: A Hollebecque; E Deutsch; C Massard; C Gomez-Roca; R Bahleda; V Ribrag; C Bourgier; V Lazar; L Lacroix; A Gazzah; A Varga; T de Baere; F Beier; S Kroesser; K Trang; F T Zenke; M Klevesath; Jean-Charles Soria Journal: Invest New Drugs Date: 2013-12 Impact factor: 3.850